Release date: 2016-06-07
The researchers said that a new drug has brought hope to patients with triple-negative breast cancer, and it should be emphasized that triple-negative breast cancer is a particularly strong disease.
A recent study found that the current three-negative breast cancer treatment program can be maintained for nearly six months, and the cancer condition is no longer developed, and the treatment effect is twice that of other treatments. This is also the second innovative treatment option that is urgently approved by the US.
The treatment regimen is the use of an antibody drug in combination with a chemotherapeutic drug.
"Antibody drugs can detect cancer cells, and after locating cancer cells, bring chemotherapeutic drugs to cancer cells," said Dr. Aditya Bardia, a research physician at the Massachusetts General Hospital Cancer Center. “This is the key reason why we can improve the therapeutic effect of chemotherapy on cancer.â€
The treatment is called sacituzumab govitecan (an antibody drug conjugate, abbreviated as: IMMU-132), which acts like a "smart bomb," the researchers said.
The antibody targets the specific protein marker of triple-negative breast cancer, Trop-2, which specifically recognizes the protein and ensures that damage to healthy tissue surrounding the cancer cell has been minimized, Bardia said.
It’s really important to keep the condition stable for nearly six months,†said Dr. Linda Bosserman, a clinical assistant professor at the California Institute of Hope Medicine, who was not involved in the study.
Bosserman said the researchers found that the drug also enabled potential long-term disease control in some patients.
If the clinical effects of the drug are confirmed, she adds, “Then I will advise patients to take this medication because it is not only effective, but also less destructive, and it does not treat cancer at the same time. Causes major disease symptoms, which improves the quality of life of patients."
The US Food and Drug Administration believes that this new drug occupies a "breakthrough" position and accelerates the development of treatment options for cancer patients. The drug may soon be approved by the official department, Bardia said.
The study was manufactured by the manufacturer Immunomedics Inc. The findings of the study were published at the annual meeting of the American Society of Clinical Oncology in Chicago on Friday. The findings of the study published at such meetings are generally considered preliminary until the relevant articles are published in a journal reviewed by peer experts.
Source: Noble
Adhesive Wound Dressing,Medical Small Wound-Care Plaster,Medical Waterproof Transfusion Wound Plaster,Medical Elastic Adhesive Aid-Band
Surgimed Medical Supplies Co.,Ltd , https://www.surgimedcn.com